Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years old.

• Body mass index (BMI) 18.5-45 kg/m2

• English-speaking

• ECOG performance status of 0 or 1

• Histologically confirmed resectable stage IIIB-D or oligometastatic Stage IV cutaneous melanoma or locally invasive/advanced mucosal melanoma as determined by multidisciplinary review

• Planned initiation of standard-of-care neoadjuvant Ipilimumab + Nivolumab or Nivolumab + Relatlimab

• Measurable disease per RECIST 1.1

• WOCP must have negative UPT within 1 week of beginning dietary intervention.

• Self-reported willingness to eat the provided foods (with some tailoring to their food preferences)

⁃ Self-reported willingness to comply with scheduled visits, undergo venipuncture, provide stool samples.

⁃ Archival tissue specimen or planned to undergo tumor biopsy as part of standard of care treatment.

Locations
United States
Texas
MD Anderson Cancer Center
RECRUITING
Houston
Contact Information
Primary
Jennifer McQuade, MD
mcquade@mdanderson.org
(713) 745-9947
Time Frame
Start Date: 2024-09-16
Estimated Completion Date: 2030-09-01
Participants
Target number of participants: 35
Treatments
Experimental: Prebiotic food-enriched diet (PreFED)
Participants will identified from the clinic schedules and/or referred from participant's treating oncologists.
Related Therapeutic Areas
Sponsors
Leads: M.D. Anderson Cancer Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials